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IT has been estimated that each year approximately 30 million American men undergo measurement of PSA for prostate cancer early detection. 1 Although men with low PSA frequently harbor prostate cancer, such men are at extremely low long-term risk of metastatic disease. 2, 3 On the other hand, most men with modestly elevated PSA do not have prostate cancer. 4 Therefore, efforts to improve the PSA test have focused on increasing specificity rather than sensitivity. As a result, novel prostate screening tests are typically developed as reflex tests to be used when PSA is elevated.
One such test is the 4-kallikrein panel, now commercially available as the 4Kscore. This statistical model includes blood levels of 3 PSA isoforms (total, free and intact PSA) plus an additional kallikrein marker (hK2) and clinical data on age, DRE status and history of prior negative biopsy. The panel was initially validated in a series of studies on ERSPC cohorts. 5e11 A subsequent statistical model was developed for use in plasma samples with an initial study in the ProtecT trial 12 and subsequent validation in both Swedish 13 and American 4 clinical cohorts. In all studies the AUC for the discrimination of high grade prostate cancer on biopsy was close to or in excess of 0.80. Improvement in AUC compared to models including clinical data alone, such as PSA and DRE, was typically on the order of 0.08.
Several prostate cancer markers are intended for use in what has been termed the "diagnostic gray zone," that is men with PSA less than 10 ng/ml and negative DRE. An obvious example is the Prostate Health Index, which has approval from the FDA (Food and Drug Administration) only within the gray zone.
14 Previously reported studies of the 4-kallikrein panel have by contrast included men with positive DRE and PSA greater than 10 ng/ml. The favorable result of these studies might be seen as justifying the use of the panel outside the diagnostic gray zone. However, it is perfectly possible for the panel to have poor properties in this small group of men but on the average across all men to indicate good diagnostic performance.
In this study we performed an individual patient data meta-analysis using data from prior studies of the kallikrein panel to determine its value for predicting high grade prostate cancer in men with a positive DRE, or PSA 10 ng/ml or greater.
METHODS
Although a meta-analysis typically starts with a literature review, the kallikrein assays were developed and then patented by one of us (HL) and the statistical algorithm was developed by one of us (AV). Studies of the panel are not practical without the involvement of the investigators to advise on assays and algorithms. Thus, all relevant studies are personally known to the investigators and no literature search was indicated.
Studies were included if the kallikrein panel was measured in men undergoing biopsy for prostate cancer, in whom the panel was measured blindly and all men were biopsied irrespective of kallikrein results. Raw data were obtained on age, PSA, DRE, stage, prior biopsy status, biopsy outcome, biopsy grade and kallikrein marker levels. DRE was defined as in the original study, typically, as the presence of nodularity. Data were received from the ProtecT, 12 Rotterdam ERSPC, 5, 8 Rotterdam Repeat Biopsy, 10 UPCA, 13 Tarn ERSPC, 9 G€ oteborg ERSPC 6,7 and OPKO Health (Miami, Florida) 4 cohorts. In the ProtecT cohort, some men had measurements available from both plasma and serum PSA samples, in which case the plasma measurements were used. 12 We did not obtain permission to use data on the Stockholm 2 cohort 15 in this analysis. One study in which the kallikrein panel was evaluated was not included due to the small sample size of only 9 total high grade cancers.
11
Patients who had PSA levels higher than 25 ng/ml were excluded from all analyses as these patients are given a uniformly high risk by the kallikrein panel. The models were assessed in 2 separate cohorts, including 1) men with high PSA, defined as PSA 10 ng/ml or greater and 25 or less and 2) men with a positive DRE. The ProtecT cohort was not included in the latter analysis as DRE results were not available. 12 A base model and a kallikrein model including the panel of 4 kallikrein markers were used to generate predictions of the risk of high grade cancer for each patient. The 4-kallikrein and base models used for these predictions were the same as those used in the original study publications. The supplementary material (http:// jurology.com/) provides further details of the exact models used for each cohort. The cohorts represented independent validations of a previously specified statistical model, including G€ oteborg previously screened, 6 OPKO Health, 4 Rotterdam, 5, 8 Rotterdam repeat biopsy, 10 Tarn   9 and UPCA. 13 The OPKO Health 4 and UPCA 13 cohorts constituted independent validation for the kallikrein statistical model currently used in contemporary practice. For each cohort we assessed discrimination by calculating the AUC. The AUC and the SE of the AUC were meta-analyzed across cohorts, and fixed effects and random effects estimates are reported. The difference in AUC between the base model and kallikrein model was calculated for each cohort with the SE of this difference estimated by bootstrap methods. The change in AUC with the addition of the kallikrein markers and the bootstrapped SEs were then entered into a meta-analysis.
Clinical impact was assessed by calculating the number of men at low risk and reporting the number of these men at low risk who were found to have high grade disease (ie false-negative results). Low risk was defined by having a predicted probability of high grade disease that was less than the prespecified threshold of 7.5% or 10%. These results were then converted into net benefit 16, 17 and compared to the default strategy of biopsying all men at risk. These analyses were restricted to 2 cohorts that used contemporary biopsy schemes and in which a prespecified statistical model was applied, that is independent validation studies (OPKO Health 4 and UPCA 13 ). We also performed several sensitivity analyses. First, the analyses were repeated for the outcome of any grade cancer in men with high PSA. This was on the grounds that in some risk stratification schemes a patient with low grade cancer is not considered at low risk if PSA is greater than 10 ng/ml. Note that we used the same models as for high grade cancer and assessed discrimination but not calibration or clinical utility as the models are not calibrated for the end point of any cancer.
Analyses were also performed that assessed serum and plasma model predictions separately, Rotterdam rounds 1, 2 and 3 as separate cohorts, and model predictions from models with and without DRE separately. Sensitivity analysis was performed that included only the cohorts that were independent validations. Among men with positive DREs sensitivity analysis was performed that included only those with PSA less than 10 ng/ml. All analyses were performed with StataÒ, version 13.
RESULTS
A total of 1,198 men from 8 cohorts were included in the individual data meta-analysis of men with PSA 10 to 25 ng/ml. There were 1,835 men from a total of 7 cohorts with positive DRE. Table 1 lists patient and disease characteristics. Supplementary tables 1 and 2 (http://jurology.com/) show characteristics separately by cohort. Cohort characteristics were similar with the exception that as expected contemporary cohorts had a higher prevalence of Gleason 7þ disease due to extended biopsy and changes in grading practice. Table 2 presents the AUCs and overall meta-analytic estimates among men with PSA 10 to 25 ng/ml and separately for men with positive DRE for the base models and the kallikrein models.
For men with PSA 10 to 25 ng/ml the base model AUCs ranged from 0.62 to 0.80 with an overall fixed effects estimate of 0.69 (95% CI 0.66, 0.72). AUCs for the kallikrein panel were 0.78 to 0.96 with an overall estimate of 0.84 (95% CI 0.81, 0.86). The meta-analytic estimate for the increase in AUC associated with the panel is 0.128 (95% CI 0.098, 0.159). The smallest increment in AUC for any study was 0.07. Hence the kallikrein panel clearly retains higher discriminative accuracy in these cohorts of men with PSA of 10 to 25 ng/ml compared to the base model.
Among men with a positive DRE, the discrimination of the base models was slightly higher than among men with PSA of 10 to 25 ng/ml, although kallikrein model discrimination was similar. Base model discrimination across cohorts was between 0.59 and 0.75, with an overall fixed effects estimate of 0.72 (95% CI 0.69, 0.75). Discrimination of the kallikrein model ranged from 0.75 to 0.86. The overall meta-analytic estimate for these models was 0.82 (95% CI 0.80, 0.84) with an estimated increase in AUC of 0.092 (95% CI 0.069, 0.115). Again, it is clear that the kallikrein panel retained higher discriminatory accuracy than the base model in men with positive DRE. Table 2 shows heterogeneity statistics. Although there is evidence that model discrimination varies among studies, there is no significant heterogeneity for the increment in discrimination afforded by the panel.
To assess the clinical impact of using the kallikrein panel outside the diagnostic gray zone, we calculated the number of men who would be advised against biopsy on the basis of low risk from the kallikrein panel and what proportion of those men were found to have high grade cancer at biopsy (table 3) . These analyses were only performed in the OPKO Health 4 and UPCA 13 cohorts as they were independent validation studies of the contemporary 4Kscore model. Figures 1 and 2 show the net benefit in men with PSA 10 to 25 ng/ml or positive DRE across a wide range of threshold probabilities. The kallikrein panel had a higher net benefit than biopsying all men at threshold probabilities greater than a 5% risk of high grade cancer. Several sensitivity analyses were performed. A sensitivity analysis for the outcome of any grade cancer found that discrimination was similar for any grade and high grade cancers among men with PSA 10 to 25 ng/ml. The overall fixed effects estimate was 0.66 (95% CI 0.62, 0.69) for base models 26 (9) 1 (3.8) Figure 1 . Decision curve analysis in independent cohorts using contemporary statistical model to predict high grade disease in men with PSA 10 to 25 ng/ml or positive DREs. Red curve indicates biopsy in no men. Blue curve indicates biopsy in all men. Green curve indicates biopsy according to 4Kscore.
and 0.82 (95% CI 0.79, 0.84) for kallikrein models (table 4) . Heterogeneity was again significant for the absolute levels of discrimination of the kallikrein and base models but not significant for the increment in AUC. Models without DRE were analyzed separately from models with DRE, with no significant differences found. Plasma cohorts and serum cohorts were compared separately with similar results. Findings were also consistent when the Rotterdam cohort was analyzed according to our prior studies, that is, unscreened men 8 separately from those with prior screening. 5 Results were also virtually unchanged in the analysis restricted to independent validation sets. For men with PSA 10 to 25 ng/ml discrimination was similar for the base model (0.72 vs 0.69 in all cohorts) and the kallikrein model (0.87 vs 0.84 in all cohorts). Among men with positive DRE in these 6 cohorts AUCs were similar for the base models (both 0.72) and the kallikrein models (both 0.82).
There were 1,588 patients included in the sensitivity analysis restricted to men with positive DRE and PSA less than 10 ng/ml. Discrimination was slightly lower for the base and kallikrein panel models compared to all men with positive DRE. Base model discrimination ranged from 0.57 to 0.69. The overall fixed effects estimate was 0.66 (95% CI 0.62, 0.69). Kallikrein model discrimination across the 7 cohorts was between 0.70 and 0.82 with an overall estimate of 0.78 (95% CI 0.75, 0.81). Similar to the main analyses, net benefit for the model was higher than the net benefit for biopsying all at thresholds of 7.5% (0.177 vs 0.165) and 10% (0.163 vs 0.142).
DISCUSSION
We found that the 4-kallikrein panel contributed importantly enhanced discrimination in men outside the diagnostic gray zone. For men with PSA 10 ng/ml or greater and 25 or less, or with positive DRE the panel of 4 kallikrein markers was associated with an increase in AUC of 0.09 to 0.13 compared to base models that included PSA but not the additional kallikrein markers. We also observed that use of the panel had clinical net benefit with the number of missed high grade cancers too small to offset larger decreases in biopsy rates. The proportion of men outside the diagnostic gray zone to whom the panel could be applied was nontrivial. In the validation study in the United States, for instance, about 1 of 4 men had PSA between 10 and 25 ng/ml, and fully 1 of 3 had PSA 10 to 25 ng/ml or a positive DRE. 4 These results have clear clinical implications. It is normally assumed that reflex tests such as the 4-kallikrein panel should only be used in the diagnostic gray zone of PSA 3 to 10 ng/ml and negative DRE. 14 We found that using the kallikrein panel outside the diagnostic gray zone would reduce number of biopsies without delaying the diagnosis of an undue number of high grade cancers. Our findings reflect the study of Lazzeri et al, who found that the Prostate Health Index retained discriminative accuracy in men with PSA 10 ng/ml or greater (AUC 0.81). 18 However, in contrast to our results, the Prostate Health Index was not favored in a decision analysis.
With that said, there remains the question of whether urologists would be comfortable recommending against biopsy in a man with high PSA or an abnormal DRE. For instance, consider 3 actual patients, including a 65-year-old man with prior negative biopsy, negative DRE and PSA 20 ng/ml, a 51-year-old man without prior biopsy, negative DRE and PSA 13 ng/ml, and a 66-year-old man with prior negative biopsy, positive DRE and PSA 11 ng/ml. The risks from the panel for these 3 men were 3.0%, 5.9% and 6.1%, respectively, and none had cancer. But one might reasonably hypothesize that most urologists would insist on biopsy for a PSA of 20 ng/ ml, a PSA of 13 ng/ml in a young man or a patient with both a positive DRE and a PSA greater than 10 ng/ml. Konety et al performed an impact study on the 4Kscore in 611 patients seen by 35 academic and community urologists who ordered the 4Kscore as part of routine clinical practice. 19 Use of the 4Kscore led to a 65% reduction in biopsy rates with the probability of biopsy strongly dependent on the 4Kscore result. Although PSA levels were not reported, it is of note that the rate of positive DRE was low at 6%, suggesting that men with a positive DRE were recommended for biopsy without further reflex testing. A subsequent impact study focusing on patients at higher risk is warranted.
CONCLUSIONS
An important proportion of men who present for biopsy fall outside the diagnostic gray zone since they have a positive DRE or PSA 10 to 25 ng/ml. The 4-kallikrein panel had good discrimination in these men and use of the panel reduced biopsy rates in this group by more than 20%. Using the panel in men with positive DRE or PSA 10 to 25 ng/ml is justified.
